Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Early VC
Total Funding
$110M
Headquarters
Menlo Park, California
Founded
2021
Artera.ai focuses on personalizing prostate cancer therapy through its main product, the ArteraAI Prostate Test, which is a clinical laboratory test designed for actual medical use. This test employs advanced multi-modal deep learning techniques to analyze patient data and provide tailored treatment options. Unlike many competitors, Artera.ai's test is based on rigorous randomized phase III clinical trials, ensuring its reliability and effectiveness. The company serves healthcare providers, hospitals, and individual patients, generating revenue through the sale of its prostate test. Artera.ai aims to enhance the treatment of prostate cancer by offering a more personalized approach, while also committing to continuous improvement and maintaining high standards of credibility through CLIA certification.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$110M
Above
Industry Average
Funded Over
1 Rounds
Artera presenting validation data at 2025 ASCO Annual Meeting highlighting how multimodal AI platform (MMAI) is advancing personalized cancer care.
AI Study Challenges Fears of Racial Bias in Prostate Cancer Care. by Fred Pennic 05/09/2025 Leave a Comment. What You Should Know: – Artera, a company developing multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the publication of a significant validation study in the JCO Clinical Cancer Informatics. – The study rigorously assessed Artera’s MMAI model and confirmed its ability to perform similarly across different racial subgroups using data from diverse prostate cancer clinical trials.Addressing the Challenge of AI Racial Bias in OncologyThis research comes at a crucial time as AI tools are increasingly integrated into clinical decision-making. However, valid concerns persist that these technologies could inadvertently worsen healthcare inequities due to racial bias, particularly if developed using datasets not representative of real-world patient populations. This is a pronounced concern in prostate cancer, where African American men have historically faced a worse prognosis, partly attributed to their underrepresentation in the development of AI tools and genomic biomarkers. Many current AI models have been trained on datasets that lack diversity, raising questions about their applicability and fairness across all patient groups
Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter's ArteraAI prostate test.
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced that its MMAI platform has been named among TIME's Best Inventions of 2024 in the medical care category.
SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial intelligence (MMAI) digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence (BCR). Researchers successfully trained and validated the model for patients who experience BCR after radical prostatectomy surgery, which is strongly associated with the risk of the disease spreading. The data was presented by Dr. Todd Morgan from Michigan Medicine as an oral presentation at the 2024 AUA Annual Meeting, on Sunday, May 5, 2024. A radical prostatectomy is the removal of the prostate in a patient with prostate cancer and has served as a primary treatment for this disease for many years. However, about 20-40% of patients who undergo the procedure eventually develop BCR, which is an indicator of the cancer returning
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Early VC
Total Funding
$110M
Headquarters
Menlo Park, California
Founded
2021
Find jobs on Simplify and start your career today